Prosecution Insights
Last updated: November 15, 2026
Application No. 19/117,709

COMPOSITIONS COMPRISING WATER, CATIONIC ALPHA-1,6-GLUCAN ETHER, AND ORGANIC SOLVENT

Non-Final OA §103§DP
Filed
Apr 02, 2025
Priority
Oct 14, 2022 — provisional 63/379,507 +2 more
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nutrition & Biosciences USA
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
82%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
908 granted / 1356 resolved
+7.0% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
58 currently pending
Career history
1417
Total Applications
across all art units

Office Action

§103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-15 are rejected under 35 U.S.C. 103 as being unpatentable over DiCosimo et al (US 20210171868, pub 6/10/2021). DiCosimo et al discloses a gel type detergent composition comprising up to about 30wt% organic solvent and up to about 30wt% water (¶ 301). The glucans are present up to 90wt% (¶ 218). The glucans disclosed include alpha-glucan ethers having alpha-(1,6) glycosidic linkages present from 55-75%, alpha 1,3 glycosidic linkages present from 25-35%, and with a DoS of about 0.05 to about 3.0 (¶ 33 and claim 27). The positively charged group or cationic groups may include ammonium groups, such as substituted or quat ammoniums, including trimethyl ammonium or trimethyl ammonium hydroxyalkyl (¶¶ 149-154). The organic solvents include ethanol (¶ 405). The compositions are made via an etherification process (¶ 62). DiCosimo et al does not disclose an embodiment with the organic solvent at the disclosed range, but given the explicit teaching that organic solvents may be included up to about 30wt%, it would have been obvious to formulate and produce a composition comprising the components disclosed above and to vary each component within the range taught. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-19 are rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of U.S. Patent No. 10,822,574 and 11,352,589, each in view of DiCosimo et al (US 20210171868, pub 6/10/2021. Although the claims at issue are not identical, they are not patentably distinct from each other because the patents are based on the pregrant pub cited in the obviousness rejection above. As such, when formulating the compositions using the same alpha-glucan ether components, it would have been obvious to include additional agents disclosed by the prior art. The following also teach an alpha-1.3 glucan ether having the same properties and are each rejected in view of DiCosimo et al (US 20210171868, pub 6/10/2021 where it would be obvious to use the glucan ethers as discussed above: U.S Patent No 10,584,233 U.S Patent No 10,822,383 U.S Patent No 10,844,324 U.S Patent No 10,876,074 U.S Patent No 10,934,418 U.S Patent No 11,193,005 U.S Patent No 11,414,628 U.S Patent No 11,859,022 U.S Patent No 11,905,495 U.S Patent No 11,946,023 U.S Patent No 11,981,712 U.S Patent No 12,297,408 U.S Patent No 12,624,126 Claims 1-19 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of the following copending Application Nos. in view of DiCosimo et al (US 20210171868, pub 6/10/2021 where it would be obvious to use the glucan ethers as discussed above: U.S. Application No 17/958719 U.S. Application No 18/539541 U.S. Application No 18/621556 U.S. Application No 18/746385 U.S. Application No 18/326071 These are provisional nonstatutory double patenting rejection. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri 9:30am-6:30pm + mid-day flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Apr 02, 2025
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790444
DENDRON-POLYMER HYBRIDS AS TAILORABLE CORONAE OF SINGLE-WALLED CARBON NANOTUBES AND USES THEREOF
3y 7m to grant Granted Nov 10, 2026
Patent 12778174
COMPOSITIONS FOR USE IN THE REDUCTION OF NOCICEPTION AND OTHER HEALTH BENEFITS IN INFANTS AND YOUNG CHILDREN
4y 4m to grant Granted Nov 03, 2026
Patent 12782339
SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES
3y 9m to grant Granted Nov 03, 2026
Patent 12779056
AGENT FOR DETECTING INTERACTION BETWEEN TISSUES AND ORGANS
3y 6m to grant Granted Nov 03, 2026
Patent 12778862
STABLE BIOACTIVE GLASS FORMULATIONS
2y 6m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
82%
With Interview (+15.3%)
Low
PTA Risk
Based on 1356 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month